Literature DB >> 9815554

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

J Steinberg1, R Oyasu, S Lang, S Sintich, A Rademaker, C Lee, J M Kozlowski, J A Sensibar.   

Abstract

Our previous observations in LNCaP cells in vitro demonstrated an association between apoptotic cell death resistance and SGP-2 (Clusterin) overexpression. Accordingly, we hypothesized that high levels of cellular SGP-2 would aid in identifying biologically aggressive prostate cancer cells with unique survival advantages. To test this hypothesis, 40 archival radical prostatectomy and/or biopsy specimens of varying grades of prostate cancer were subjected to immunohistochemical SGP-2 staining. The resulting epithelial stains were quantified subjectively on a scale of 1-3 by four independent observers. Benign prostatic epithelial cells from young donors served as controls and showed a consistently weak staining intensity. In contrast, prostate cancer specimens showed varying degrees of staining intensity that correlated with a Gleason pattern (P = 0.006). This correlation supports the hypothesis that protection from apoptotic death may account, in part, for biologically aggressive tumor behavior.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815554

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Overexpression of clusterin in human breast carcinoma.

Authors:  M Redondo; E Villar; J Torres-Muñoz; T Tellez; M Morell; C K Petito
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

3.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

4.  The tumor suppressor von Hippel-Lindau gene product and metastasis: new thoughts on an old molecule.

Authors:  Debabrata Mukhopadhyay
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 5.  [Stress proteins in prostate cancer. Challenge and promise].

Authors:  B A Hadaschik; S W Melchior; R D Sowery; A I So; M E Gleave
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

6.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

7.  Plasma proteomics analysis of tamoxifen resistance in breast cancer.

Authors:  Keivan Majidzadeh-A; Javad Gharechahi
Journal:  Med Oncol       Date:  2013-10-26       Impact factor: 3.064

Review 8.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

9.  Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.

Authors:  Amina Zoubeidi; Kim Chi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

10.  Effects of clusterin over-expression on metastatic progression and therapy in breast cancer.

Authors:  Louise Flanagan; Lorna Whyte; Namita Chatterjee; Martin Tenniswood
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.